Crinetics Pharmaceuticals, Inc.
CRNX
$84.95
+0.13%
Crinetics Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product, Palsonify (paltusotine), is an FDA-approved once-daily oral treatment for acromegaly, and its pipeline includes atumelnant for congenital adrenal hyperplasia and CRN09682 for neuroendocrine tumors. The company is positioned as a niche player in the rare endocrine space, with a differentiated oral therapy platform. The current investor narrative centers on the announced acquisition by Vertex Pharmaceuticals for $10 billion, which has driven a massive re-rating of the stock, with debates about the deal's strategic value and potential for future pipeline upside.…
CRNX
Crinetics Pharmaceuticals, Inc.
$84.95
Related headlines
Investment Opinion: Should I buy CRNX Today?
Based on the data, CRNX is rated a Hold. The acquisition by Vertex at $84.85 per share provides a clear valuation anchor, and the current price is essentially at the deal price, leaving minimal upside for new investors. The analyst consensus target of $85.5 is only 0.8% above the current price, reflecting the deal's terms. The stock is not a Buy because the risk-reward is skewed to the downside if the deal fails, but it is not a Sell because the deal is likely to close, providing a floor.
Sign up to view all
CRNX 12-Month Price Forecast
The AI assessment is neutral because the stock's price is essentially tied to the acquisition outcome. If the deal closes, the stock will likely remain near $84.85, offering no upside. If the deal fails, the stock could drop significantly, making the risk-reward unattractive. The key factor is the probability of deal completion, which is high but not certain. The AI would upgrade to bullish if the acquisition price were increased or if the company's pipeline showed unexpected positive data, and downgrade to bearish if the deal were to collapse.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Crinetics Pharmaceuticals, Inc.'s 12-month outlook, with a consensus price target around $85.50 and implied upside of +0.7% versus the current price.
Average Target
$85.50
0 analysts
Implied Upside
+0.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$85 - $90
Analyst target range
Drowning in data?
Find the real signal!
Bulls vs Bears: CRNX Investment Factors
The bull case is anchored by the $10 billion acquisition at a 102% premium, which provides a clear valuation floor and validates the company's pipeline, particularly atumelnant. The bear case highlights the extreme valuation, with a P/S ratio of 568.9 and negative earnings, leaving no room for disappointment. Currently, the bull side has stronger evidence because the acquisition is likely to close, but the single most important tension is whether the deal completes as planned. If the acquisition fails, the stock could fall to its 52-week low of $30.25, a -64% downside, while successful closure caps upside at the deal price. This binary outcome dominates all other factors.
Bullish
- Vertex acquisition at 102% premium: Vertex is acquiring Crinetics for $10 billion, a 102% premium to the pre-announcement price, providing a clear floor and validating the company's pipeline. The deal is expected to close, offering shareholders a guaranteed exit at $84.85 per share, near the current price.
- Commercial launch of Palsonify: Palsonify, the first oral once-daily treatment for acromegaly, received FDA approval and generated $10.7 million in Q1 2026 revenue, up 28.7% YoY. This marks the company's transition to a commercial-stage biotech with a differentiated product in a niche market.
- Strong balance sheet with low debt: Crinetics has a current ratio of 12.3 and a debt-to-equity ratio of just 0.05, indicating ample liquidity to fund operations and pipeline development without financial distress. This reduces bankruptcy risk and supports ongoing R&D investment.
- Pipeline optionality with atumelnant: Atumelnant, a late-stage candidate for congenital adrenal hyperplasia (CAH), has blockbuster potential and could address a significant unmet need. Vertex's acquisition rationale includes this asset, which could add $5 billion in annual sales if approved.
Bearish
- Extreme valuation with negative earnings: Crinetics trades at a price-to-sales ratio of 568.9 and a forward P/E of -20.97, reflecting a market cap of $4.38 billion against just $10.7 million in quarterly revenue. The stock is priced for perfection, with no earnings support.
- Heavy operating losses and cash burn: The company reported an operating margin of -67.1% and a net margin of -60.5%, with free cash flow of -$419.5 million over the trailing twelve months. Continued losses are expected until Palsonify scales and pipeline assets mature.
- Acquisition risk of deal failure: The stock's price is nearly identical to the acquisition price of $84.85, leaving little upside if the deal closes as expected. Any regulatory or shareholder hurdles could cause a sharp decline toward the 52-week low of $30.25, a potential -64% drop.
- Dependence on single product: Palsonify is the only commercial product, and its revenue is still minimal. The company's future hinges on successful commercialization and pipeline progress, with limited diversification in the near term.
CRNX Technical Analysis
Beta
0.09
0.09x market volatility
Max Drawdown
-42.2%
Largest decline past year
52-Week Range
$31-$85
Price range past year
Annual Return
+174.1%
Cumulative gain past year
| Period | CRNX Return | S&P 500 |
|---|---|---|
| 1m | +1.7% | +2.0% |
| 3m | +160.5% | +1.0% |
| 6m | +115.0% | +11.8% |
| 1y | +174.1% | +18.1% |
| ytd | +81.8% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CRNX Fundamental Analysis
Quarterly Revenue
$10734000.0B
2026-03
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
98.1%
Latest Quarter
Free Cash Flow
$-419516000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CRNX Overvalued?
PE
-9.4x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-9.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant. The company has a negative EPS of -$1.23 in Q1 2026 and a net margin of -60.5%, indicating heavy losses. With free cash flow of -$419.5 million over the trailing twelve months, the company is burning cash rapidly, though its current ratio of 12.3 provides a cushion. Revenue is still minimal at $10.7 million per quarter, and the company's dependence on Palsonify for commercial revenue creates concentration risk. The debt-to-equity ratio is low at 0.05, but the negative operating margin of -67.1% highlights the challenge of scaling operations profitably.
